The Discounted Cash Flow (DCF) valuation of Recro Pharma Inc (REPH) is 1.97 USD. With the latest stock price at 2.09 USD, the upside of Recro Pharma Inc based on DCF is -5.7%.
Based on the latest price of 2.09 USD and our DCF valuation, Recro Pharma Inc (REPH) is a sell. selling REPH stocks now will result in a potential gain of 5.7%.
| Range | Selected | |
| WACC / Discount Rate | 8.9% - 14.1% | 11.5% |
| Long-term Growth Rate | 3.0% - 5.0% | 4.0% |
| Fair Price | 0.89 - 5.05 | 1.97 |
| Upside | -57.4% - 141.7% | -5.7% |